[Other] THE LANCET - Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel grou...

rqeeqqwq Post time 3 day(s) ago | Show all posts |Read mode
Reward10points


  • doi: 10.1016/S2213-8587(22)00387-4

    Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial

    https://www.sciencedirect.com/science/article/abs/pii/S2213858722003874?via%3Dihub

    Can i have the supplementary material?


Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

You have to log in before you can reply Login | Register

Points Rules

Intermediate member
  • post

  • reply

  • points

    400

Latest Reply

Return to the list